Medis Consulting conducted a Systematic Literature Review (SLR) to document the evidence base linking hospital design elements on patient outcomes for a large global engineering firm.

A manufacturer of primarily generic products had made an advancement in the formulation of a standard hospital antibiotic.  They wanted to bring two novel formulations to market and asked us to provide insights on the likely use and appropriate pricing of each formulation.

A leading pharmaceutical company faced the launch of one or more biosimilars on one of their leading products.  We helped them understand the likely market events and build a strategy to address them.

A large pharmaceutical company was launching a novel compound into an orphan oncology space and wanted to segment payers in order to anticipate the response and ensure the best possible access.

A large pharmaceutical client with a significant respiratory portfolio was interested in better partnering with experts in US health systems.  They ask us to find a representative group of in-house experts and identify opportunities, drivers, and barriers to partnership.

A large pharmaceutical company needed to reorganize their US hospital sales force to better address the changing dynamics of hospital systems.  We gathered insights in three pilot markets to improve their sales approach to better reflect the interests of their organized clients.

A large global pharmaceutical company had a hematology product that had long since been surprised by newer drugs, but still brought in significant revenues.  They asked us to produce a pricing tracker to improve their ability to respond and predict multiple markets and refine their value strategy.

A large pharmaceutical company was launching a potential blockbuster in the treatment of various forms of anemia.  We supported their evaluation of additional indications by gathering insights from a representative group of US payers.  We provided recommendations not only in how best to design a value message within the indication, but also in how their approval in this indication might be managed in the context of anemia overall.

A large pharmaceutical company had a well-known and profitable respiratory franchise.  As they prepared to launch a novel combination product, they asked for us to conduct a comprehensive pricing study, taking into account multiple stakeholders and the impact of the new product on the rest of their portfolio.

A clinical stage biotech company was building up commercial operations for a novel anti-epileptic.  They asked us to provide a snapshot of the reimbursement landscape they could expect, and to help them  price their product for optimal revenues and access.